During the last session, Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI)’s traded shares were 1.56 million. At the end of the trading day, the stock’s price was $13.40, reflecting an intraday loss of -1.76% or -$0.24. The 52-week high for the MRVI share is $35.22, that puts it down -162.84 from that peak though still a striking 11.27% gain since the share price plummeted to a 52-week low of $11.89. The company’s market capitalization is $3.20B, and the average intraday trading volume over the past 10 days was 4.66 million shares, and the average trade volume was 2.30 million shares over the past three months.
Maravai LifeSciences Holdings Inc. (MRVI) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 1.90. MRVI has a Sell rating from 0 analyst(s) out of 12 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $0.01.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) trade information
Maravai LifeSciences Holdings Inc. (MRVI) registered a -1.76% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.76% in intraday trading to $13.40 this Wednesday, 05/24/23, hitting a weekly high. The stock’s 5-day price performance is 4.52%, and it has moved by 0.37% in 30 days. Based on these gigs, the overall price performance for the year is -62.45%. The short interest in Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) is 7.27 million shares and it means that shorts have 2.19 day(s) to cover.
The consensus price target of analysts on Wall Street is $18.82, which implies an increase of 28.8% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $13.00 and $27.00 respectively. As a result, MRVI is trading at a discount of -101.49% off the target high and 2.99% off the low.
Maravai LifeSciences Holdings Inc. (MRVI) estimates and forecasts
Statistics show that Maravai LifeSciences Holdings Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Maravai LifeSciences Holdings Inc. (MRVI) shares have gone down -5.30% during the last six months, with a year-to-date growth rate less than the industry average at -83.33% against 17.40. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to shrink -98.10% this quarter and then drop -73.00% in the quarter after that. In the rating firms’ projections, revenue will decrease -54.10% compared to the previous financial year.
Revenue for the current quarter is expected to be $72.01 million as predicted by 11 analyst(s). Meanwhile, a consensus of 11 analyst(s) estimates revenue growth to $112.66 million by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $242.73 million and $191.26 million respectively. In this case, analysts expect current quarter sales to shrink by -70.30% and then drop by -41.10% in the coming quarter.
While earnings are projected to return 7.00% in 2023.
Maravai LifeSciences Holdings Inc. is due to release its next quarterly earnings between August 02 and August 07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI)’s Major holders
Maravai LifeSciences Holdings Inc. insiders own 0.57% of total outstanding shares while institutional holders control 98.14%, with the float percentage being 98.70%. GTCR, LLC is the largest shareholder of the company, while 314 institutions own stock in it. As of Mar 30, 2023, the company held over 21.68 million shares (or 16.44% of all shares), a total value of $303.75 million in shares.
The next largest institutional holding, with 11.76 million shares, is of Massachusetts Financial Services Co.’s that is approximately 8.91% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $164.72 million.
Also, the Mutual Funds coming in first place with the largest holdings of Maravai LifeSciences Holdings Inc. (MRVI) shares are Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. Data provided on Dec 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 3.38 million shares. This amounts to just over 2.56 percent of the company’s overall shares, with a $48.35 million market value. The same data shows that the other fund manager holds slightly less at 2.88 million, or about 2.19% of the stock, which is worth about $41.22 million.